Aβ42 vaccine on the Tg2576 Alzheimer model mice

Mikio Shoji, Yasuo Harigaya, Etsuro Matsubara, Takeshi Kawarabayashi, Tetsuro Murakami, Nobuhiko Oomori, Keiko Sato, Isao Nagano, Koji Abe

研究成果査読

1 被引用数 (Scopus)

抄録

In 1999, Schenk et al. [Nature 400 (1999) 173] reported remarkable improvement of Aβ amyloid burden in the transgenic mice brain by immunization with Aβ42 peptides. Soon after, four independent institutes showed the same findings on senile plaque amyloid and improvement of memory disturbance confirming the effect of Aβ vaccine on brain Aβ amyloidosis. In July 2001, Elan Corporation started cooperative Phase I study of AN-1792, synthetic Aβ42 peptide. In September, Phase II study of 375 Alzheimer patients began in Europe. Because of 15 cases of encephalitis in March 2002, this drug trial was suspended. This is serious accident for patients, family and specialists, who hope for a curative therapy for Alzheimer's disease (AD). However, this result provided new insight that brain amyloidosis is reversible. Prompt evaluation of candidate drugs such as anti-Aβ antibody, β-secretase inhibitor or anti-Aβ aggregation should be necessary in the near future.

本文言語English
ページ(範囲)399-403
ページ数5
ジャーナルInternational Congress Series
1252
C
DOI
出版ステータスPublished - 6月 1 2003
外部発表はい

ASJC Scopus subject areas

  • 医学一般

フィンガープリント

「Aβ42 vaccine on the Tg2576 Alzheimer model mice」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル